Abolishing signals mediated by the inhibitory receptor PD-1 results in a systemic decrease in tryptophan and tyrosine, which leads to a striking deficiency in the neurotransmitters serotonin and dopamine in the brain and anxiety-like behavior and exacerbated fear.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Repasky, E.A., Eng, J. & Hylander, B.L. Cancer J. 21, 97–103 (2015).
Glaser, R. & Kiecolt-Glaser, J.K. Natl. Rev. 5, 243–251 (2005).
Miyajima, M. et al. Nat. Immunol. 18, 1342–1352 (2017).
MacIver, N.J., Michalek, R.D. & Rathmell, J.C. Annu. Rev. Immunol. 31, 259–283 (2013).
Patsoukis, N. et al. Nat. Commun. 6, 6692 (2015).
Bengsch, B. et al. Immunity 45, 358–373 (2016).
Palmiter, R.D. Ann. NY Acad. Sci. 1129, 35–46 (2008).
Mosienko, V. et al. Transl. Psychiatry 2, e122 (2012).
Sinclair, L.V. et al. Nat. Immunol. 14, 500–508 (2013).
Carr, E.L. et al. J. Immunol. 185, 1037–1044 (2010).
Nakaya, M. et al. Immunity 40, 692–705 (2014).
Zitvogel, L., Kepp, O. & Kroemer, G. Nat. Rev. Clin. Oncol. 8, 151–160 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
V.A.B. holds patents on the PD-1 pathway licensed by Bristol-Myers Squibb, Roche, Merck, EMDSerono, Boehringer Ingelheim, AstraZeneca, Novartis and Dako.
Rights and permissions
About this article
Cite this article
Strauss, L., Patsoukis, N. & Boussiotis, V. Feeling stressed? It might be your T cells. Nat Immunol 18, 1281–1283 (2017). https://doi.org/10.1038/ni.3872
Published:
Issue Date:
DOI: https://doi.org/10.1038/ni.3872